Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux

Description

Most commonly seen in children, vesicoureteral reflux (VUR) is the retrograde flow of urine from the bladder upward toward the kidney. The primary management strategies have been prophylactic antibiotics to reduce urinary tract infections and, for higher grade disease, surgical correction of the underlying reflux. Injection of periureteral bulking agents is proposed as an alternative to surgical intervention.

OBJECTIVE

The objective of this evidence review is to determine whether endoscopic treatment with periureteral bulking agents improves the net health outcome in individuals who have vesicoureteral reflux and (a) have failed medical therapy and are eligible for surgery or (b) have not failed medical therapy and may be ineligible for surgery.

POLICY STATEMENT

Periureteral bulking agents may be considered medically necessary as a treatment of vesicoureteral reflux grades II, III, or IV when medical therapy has failed and surgical intervention is otherwise indicated.

The use of bulking agents as a treatment of vesicoureteral reflux in other clinical situations is considered investigational.
POLICY GUIDELINES

The use of bulking agents is contraindicated in patients with nonfunctioning kidney(s), Hutch diverticuli, active voiding dysfunction, and ongoing urinary tract infection.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

In 2001, Deflux was approved by the U.S. Food and Drug Administration (FDA) through the premarket application process for the "treatment of children with vesicoureteral reflux (VUR) grades II-IV" and remains the only FDA approved bulking agent for VUR. Contraindications include patients with nonfunctioning kidney(s), hutch diverticulum, ureterocele, active voiding dysfunction, and ongoing UTI. Duplicated ureters were initially considered a contraindication to Deflux treatment, but this was changed to a precaution in 2007.

Note: Polytetrafluoroethylene may migrate, causing serious adverse events; this agent is not FDA-approved. Coaptite (Merz Aesthetics), Macroplastique (Cogentix Medical), and Tegress™ (CR Bard) are categorized by FDA as "Agent, Bulking, Injectable for Gastro-Urology Use." Tegress™ was voluntarily withdrawn from the market by CR Bard in January 2007.

FDA product code: LNM.

RATIONALE

Summary of Evidence

For individuals who have VUR who have failed medical therapy and are eligible for surgery who receive endoscopic treatment with periureteral bulking agents, the evidence includes randomized controlled trials and systematic reviews. Relevant outcomes are symptoms, morbid events, and treatment-related morbidity. Overall, studies have reported similar rates of reflux resolution compared with ureteral reimplantation surgery and the body of evidence would suggest that morbidity rates are similar or lower with bulking agents. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have VUR who have not failed medical therapy and may be ineligible for surgery who receive endoscopic treatment with periureteral bulking agents, the evidence includes randomized controlled trials. Relevant outcomes are symptoms, morbid events, and treatment-related morbidity. The randomized controlled trials, which had relatively small sample sizes in each arm, compared periureteral bulking agents with antibiotic prophylaxis and/or surveillance only and reported mixed findings. Additional, larger studies are needed before conclusions can be drawn about the efficacy of periureteral bulking agents as first-line treatment for patients with VUR. The evidence is insufficient to determine the effects of the technology on health outcomes.
SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

European Association of Urology

In 2012, the European Association of Urology published guidelines on the diagnosis and treatment of vesicoureteral reflux (VUR) in children. The Association recommended continuous antibiotic prophylaxis as initial treatment for children diagnosed with VUR in the first year of life and for children ages 1 to 5 years who present with high-grade VUR. For children ages 1 to 5 with lower grade VUR and no symptoms, surveillance without antibiotic prophylaxis is considered a reasonable option. The guidelines indicated that a surgical correction is a treatment option for patients with persistent symptoms and that endoscopic injection of bulking materials can have satisfactory results in children with lower grades of VUR.

American Urological Association

In 2017, the American Urological Association reviewed and confirmed the validity of its 2010 published guideline on the management of primary VUR in children. The Association recommended that patients older than 1 year of age who have a febrile breakthrough urinary tract infection while receiving continuous antibiotic prophylaxis be considered for open surgery or endoscopic injection of bulking agents. Specific bulking agents mentioned were Deflux and Macroplastique. The guideline was based on a review of the evidence, but its authors acknowledged the lack of robust RCT data.

U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force has not addressed the use of injectable bulking agents to treat VUR.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES


**POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2012</td>
<td>New policy</td>
<td>Policy updated with literature review, References 8-9, 17-19, and 23 added, other references renumbered. Policy statements unchanged.</td>
</tr>
<tr>
<td>March 2015</td>
<td>Replace</td>
<td>Policy updated with literature review through June 22, 2017; no references added. Policy statements unchanged but &quot;not medically necessary&quot; corrected to &quot;Investigational&quot;.</td>
</tr>
<tr>
<td>December 2017</td>
<td>Replace</td>
<td>Policy updated with literature review through June 7, 2018; no references added. Policy statements unchanged.</td>
</tr>
<tr>
<td>December 2018</td>
<td>Replace</td>
<td>Policy updated with literature review through May 31, 2019. no references added. Policy statements unchanged.</td>
</tr>
<tr>
<td>December 2019</td>
<td>Replace</td>
<td>Policy updated with literature review through June 29, 2020; references added. Policy statements unchanged.</td>
</tr>
</tbody>
</table>

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.